Last reviewed · How we verify
Methocillin S (CLOXACILLIN)
Methocillin S (Cloxacillin) is a small molecule antibiotic developed by GlaxoSmithKline, currently owned by the same company. It is classified as a cloxacillin and was FDA-approved in 1974 for various bacterial infections, including those caused by Staphylococcus aureus. The drug is available as a generic medication, with multiple manufacturers, and is off-patent. Methocillin S is used to treat a range of infections, including acute bacterial sinusitis, osteomyelitis, and skin infections. It is not patented and is widely available.
At a glance
| Generic name | CLOXACILLIN |
|---|---|
| Sponsor | GSK |
| Drug class | cloxacillin |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Acute bacterial sinusitis
- Continuation Therapy for Acute Osteomyelitis
- Continuation Therapy for Chronic Osteomyelitis
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Lower respiratory tract infection
- Pharyngitis
- Sinusitis
- Staphylococcal meningitis
- Staphylococcal pneumonia
- Staphylococcal septicemia
- Staphylococcus Aureus Bronchitis
- Staphylococcus Aureus Urinary Tract Infection
- Staphylococcus Epidermidis Urinary Tract Infection
Common side effects
Key clinical trials
- Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin (NA)
- Aminoglycosides in Early Sepsis (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Unbound Cloxacillin Concentrations During Continuous Infusion (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia (NA)
- Antibiotic Concentrations Among Critically Ill Patients
- Staphylococcus Aureus Network Adaptive Platform Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methocillin S CI brief — competitive landscape report
- Methocillin S updates RSS · CI watch RSS
- GSK portfolio CI